Your email has been successfully added to our mailing list.

×
0 0 0.000337799797320134 0.00123859925684044 -0.00225199864880084 -0.00484179709492166 -0.00461659723004162 -0.00461659723004162
Stock impact report

SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear [Seeking Alpha]

SpringWorks Therapeutics, Inc. - common stock (SWTX) 
Last springworks therapeutics, inc. - common stock earnings: 3/12 04:30 pm Check Earnings Report
Company Research Source: Seeking Alpha
The company is now facing the challenge of successfully commercializing its therapy. With rapidly growing losses and its hefty market cap SpringWorks Therapeutics is a "Hold". SpringWorks ( NASDAQ: SWTX ) joined the ranks of commercial stage biotechs with FDA approval of its Nirogacestat (OGSIVEO) in treatment of adult patients with progressing desmoid tumors who require systemic treatment. It is now undergoing a new critical test as it works Recommended For You Recommended For You Show less Read more
Impact Snapshot
Event Time:
SWTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
SWTX alerts

from News Quantified
Opt-in for
SWTX alerts

from News Quantified